2型糖尿病肾脏疾病患者血清SAA-LDL水平与oxLDL的关系研究被引量：1

Relationship between Serum Amyloid A-low-density Lipoprotein Complex and Oxidized Low Density Lipoprotein in Diabetic Kindney Disease of Type 2 Diabetes

下载PDF

导出

摘要目的研究2型糖尿病肾脏疾病(T2DKD)病人血清中血清淀粉样蛋白A-低密度脂蛋白(serum amyloid A-low-density lipoprotein complex,SAA-LDL)水平变化及其与氧化型低密度脂蛋白(oxidized low density lipoprotein,ox LDL)的相关关系。方法按尿微量清蛋白/尿肌酐比(Urine Albumin-to-Creatinine Ratio,UACR)水平将260例T2DM病人分3组:单纯糖尿病(SD组,n=80),早期糖尿病肾脏疾病(ED组,n=86)和临床糖尿病肾脏疾病(CD组,n=94),另选体检中心体检健康者作为对照(NC组,80例),分别测定各组血清空腹血糖(FGP),糖化血红蛋白(Hb A1c),超敏C反应蛋白(hs CRP),ox LDL,SAA-LDL,低密度脂蛋白质胆固醇(LDL-C)等相关指标并进行相关分析。结果 SD组,ED组,CD组血清SAA-LDL和ox LDL水平较对照组升高并随清蛋白尿水平升高而增加。SAA-LDL与hs-CRP,ox LDL正相关(r=0.871,P<0.05;r=0.762,P<0.05)。结论 T2DKD患者SAA-LDL水平明显升高,SAA-LDL与hs-CRP,ox LDL正相关,SAA-LDL可能促进T2DKD发生,发展。 Objective To study the relationship between serum amyloid A- low- density lipoprotein complex（ SAA- LDL）and oxidized Low density Lipoprotein（ ox LDL） in diabetic kindney disease of type 2 diabetes. Methods SAA- LDL and ox LDL of blood serum were measured by double antibody enzyme linked inmmunosorbent assay. Results Compare with control group,serum level of SAA- LDL and ox LDL were distinctly lower[（ 28. 56 ± 3. 24,39. 56 ± 6. 78,51. 23 ± 9. 12 vs 15. 11 ± 2. 14,P〈0. 05）,（ 396. 19 ± 18. 46,475. 34 ± 29. 17,599. 10 ± 35. 21 vs 289. 22 ± 14. 32,P〈0. 05） ],and correlation analysis suggested that serum of SAA- LDL were positively correlated with ox LDL and CRP（ r = 0. 871,P〈0. 05; r = 0. 762,P〈0. 05）. Conclusion The serum SAA- LDL of level was distinctly higher,and was positively correlated with ox LDL and CRP,and is closely related to the diabetic kindney disease of type 2 diabetes.

作者张高明张国明郭绪晓杨莉马小波韩洪波

机构地区沭阳县人民医院山东中医药大学附属医院检验科

出处《牡丹江医学院学报》 2015年第5期18-20,共3页 Journal of Mudanjiang Medical University

关键词 2型糖尿病肾脏疾病淀粉样蛋白A-低密度脂蛋白复合物氧化低密度脂蛋白尿清蛋白尿蛋白 type 2 diabetes diabetic kindney disease serum amyloid A-low-density lipoprotein complex oxidized low density lipoprotein urinary albumin

分类号 R54 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献12

1Nation Kidney Foundation.KDOQITM clinical practice guideline and clinicalpractice recommendation for diabetes and chronic kidney disease[J].Am J Kidney Dis,2007,49(Suppl 2):S1-S180.
2张国明,胡礼仪,于琦,王满响.2型糖尿病肾病血清氧化型低密度脂蛋白与尿清蛋白排泄率关系的研究[J].现代检验医学杂志,2010,25(2):90-91. 被引量：1
3Lehmann R,Schleiher ED.Molecular mechanism of diabetic nephropathy[J].Clin Chim Acta,2000,297(1):135.
4Mashiba S,Ogasawara K,Wada Y,et al.Development of blood examination method of serum amylid A and LDL complex,and clinical application to prediction of cardiovascular event[J].Rinsho Byori,2004,52:67-74.
5Ogasaware K,Mashiba S,Wada Y,et al.A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease[J].Atherosclerosis,2004,174:349-356.
6张瑞英,许小进,富路,沈景霞,姜波涛.血清淀粉样蛋白A和血清淀粉样蛋白A-低密度脂蛋白复合物与冠心病的临床研究[J].中华老年心脑血管病杂志,2010,12(2):123-126. 被引量：4
7Kotani K;Koibuchi H;Yamada T,et al.The effects of lifestyle modification on a new oxidized low-density lipoprotein marker,serum amyloid A-LDL,in subjects with primary lipid disorder[J].Clinica chimica acta;2009,409(1-2):67-69.
8Kotani K;Satoh N;Kato Y,et al.A novel oxidized low-density lipoprotein marker,serum amyloid A-LDL,is associated with obesity and the metabolic syndrome[J].Atherosclerosis.2009,204(2):526-531.
9Kotani K,Satoh N,Yamada T.Bezafibrate and serum amyloid A-low-density lipoprotein complex in patients with type 2 diabetes mellitus and hypertriglyceridemia[J].European journal of internal medicine.2010 21(2):e10.
10Kotani K1,Asahara-Satoh N,Kato Y,et al.Remnant-like particle cholesterol and serum amyloid A-low-density lipoprotein levels in obese subjects with metabolic syndrome[J].Journal of clinical lipidology.2011 5(5):395-400.

二级参考文献14

1O'Brine KD, Chait A. Serum amyloid A: the"other" inflammatory Portein. J Curr Arterioscler Rep, 2006,8 :62-68.
2Mashiba S, Ogasawara K, Wada Y, et al. Development of blood examination method of serum amyloid A and LDL complex,and clinical application to prediction of cardiovascular event. Rinsho Byori, 2004,52 : 67-74.
3Ogasawara K, Mashiba S, Wada Y, et al. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis,2004,174:349-356.
4Gensini GG.A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983,51:606.
5Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells:implications for serum amyloid A function. Proc Natl Acad Sci USA, 1994,91 : 3186- 3190.
6Mezaki T, Matsubara T, Hori T, et al. Plasma levels of soluble thrombomodulin,C-reactive protein,and serum amyloid A protein in the atherosclerotic coronary circulation. Jpn Heart J, 2003,44:601-612.
7Chait A, Lewis K, Tannock L, et al. Nutrition and inflammation role of dietary cholesterol. Int Congress Series, 2004, 1262:313-316.
8Sjohotm K,Palming J,Olofsson LE, et al. A microarray search for genes predominantly expressed in human omental adipocytes:adipose tissue as a major production site of serum amyloid A. Clin Endocrinol Metab, 2005,90 : 2233-2239.
9Kotani K,Satoh N,Kato Y,et al. The Japan Obesity and Metabolic Syndrome Study Group. A novel oxidized low density lipoprotein marker,serum amyloid A-LDL,is associated with obesity and the metabolic syndrome. Atherosclerosis, 2009, 204:526-531.
10Kotani K,Koibuchi H, Yamada T,et al. The effects of lifestyle modification on a new oxidized low-density lipoprotein marker,serum amyloid A-LDL,in subjects with primary lipid disorder. Clin Chim Acta, 2009,409 : 67-69.